Abstract 3117
Background
Cancer patients undergoing chemotherapy experienced many adverse effects. The purpose of this study was to assess the symptoms were experienced by cancer patients using the Edmonton Symptom Assessment scale.
Methods
The study was cross-sectional and was conducted in one-day clinic in large oncology hospital in capital of Greece. The sample consisted of 199 cancer patients undergoing chemotherapy in cycle 3. Date was collected using Edmonton Symptom Assessment Scale (ESAS) additionally with a questionnaire for demographic and clinical characteristics, Descriptive and conductive statistical methods were used.
Results
The vast majority of patients were women (n = 153, 76.9%) and had breast cancer (n = 153, 76,9%). Patients experienced mild severity symptoms as could be seen from the mean values of symptoms (physical symptoms: 14.85±10.25, emotional symptoms: 6.84±5.24, well-being 3.73±2.61). There is a statistically significant difference between type of cancer and shortness of breath (p = 0.015) between gender and nausea (p = 0.013) gender and shortness of breath (p = 0.013). In addition, there is statistically difference between drowsiness and how is chemotherapy given (p = 0.0017). The rest of the comparisons revealed that there is a statistical significant difference between pain and type of chemotherapy regimen (p = 0.014), nausea and type of chemotherapy regimen (p = 0.012), well-being and type of chemotherapy regimen (p = 0.003) as well as between total symptoms and type of chemotherapy regimen (p = 0.025).
Conclusions
Edmonton Symptom Assessment Scale was an important clinical instrument for assessing symptoms in clinical practice. There is a need for further research in order to use this tool in a daily clinical practice in one day chemotherapy clinic.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4506 - Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity
Presenter: Adel Samson
Session: Poster Display session 3
Resources:
Abstract
1631 - Randomized phase 2 clinical trial of NY-ESO-1 protein vaccine combined with cholesteryl pullulan (CHP-NY-ESO-1) in resected esophageal cancer patients
Presenter: Shinichi Kageyama
Session: Poster Display session 3
Resources:
Abstract
4244 - T cell repertoire sequencing reveals dynamics of response to dendritic cell vaccine plus dasatinib for checkpoint blockade resistant metastatic melanoma
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
5791 - Ixovex, a novel oncolytic E1B-mutated adenovirus
Presenter: Mohiemen Anwar
Session: Poster Display session 3
Resources:
Abstract
4170 - Anti-CSPG4 DNA vaccination as a promising strategy for the treatment of CSPG4+ tumors: a comparative oncology trial
Presenter: Federica Riccardo
Session: Poster Display session 3
Resources:
Abstract
5780 - Antitumor activity, immunogenicity and safety of a novel PD-1 vaccine in combination with two chimeric HER-2 peptide vaccine in syngeneic Balb/c, C57Bl/6 models and in beagle dogs
Presenter: Pravin Kaumaya
Session: Poster Display session 3
Resources:
Abstract
5860 - Maternal immunization against ALK as a weapon to fight neuroblastoma
Presenter: Giuseppina Barutello
Session: Poster Display session 3
Resources:
Abstract
4720 - Phase 1 study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumors
Presenter: Jason Luke
Session: Poster Display session 3
Resources:
Abstract
5717 - Anti-PD-L1/IL-15 fusion protein generates robust adaptive immune gene signatures in tumors leading to tumor inhibition and memory responses
Presenter: Stella Martomo
Session: Poster Display session 3
Resources:
Abstract
1802 - Evaluation of the anti-tumor efficacy and immune effects of N-809, a novel IL-15 superagonist/anti-PD-L1 bispecific agent
Presenter: Kristin Hicks
Session: Poster Display session 3
Resources:
Abstract